Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Experts discuss evolving therapies for EGFR-mutated metastatic NSCLC, comparing combination regimens and their impact on patient outcomes.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The decision from the Ministry of Health, Labour and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.